London, United Kingdom
MediSieve is a London-based biotech startup that has developed Magnetic Haemofiltration, a groundbreaking platform therapy capable of removing specific substances from patients' bloodstream. This technology can be utilized as a direct treatment, to enhance the safety and effectiveness of other therapies, or to enable personalized medicine. The potential markets for this product span across oncology, infectious diseases, auto-immune diseases, poisoning, and drug overdose, representing multi-billion-dollar opportunities. Notably, Magnetic Haemofiltration has demonstrated rapid and effective removal of IL-6 from human plasma.
The company, established in 2015, has already raised £4M in equity funding and secured over £4M in non-dilutive grants. Currently, they are seeking an additional £8M at Series A to support pivotal clinical trials and regulatory approvals, with eligibility for EIS. MediSieve's notable recognition includes features in leading media publications such as the Sunday Telegraph, Daily Mail, and Wired Magazine. Moreover, the company has achieved success in various startup competitions and its founder, George Frodsham, has been honored with the BBSRC Innovator of the Year and MIT Innovators Under 35 awards.
Notably, the latest £1.60M grant investment in June 2021 was secured from UK Research and Innovation. The technology has completed pre-clinical validation, including animal studies, and is projected to commence clinical studies in Q2 2022. As a result of its innovative approach and potential, MediSieve presents an exciting opportunity for venture capital investors looking to participate in the biotechnology, health care, medical devices, and health and wellness industries.
